CoChat

Comparison of the Effects of Pioglitazone and Metformin on Hepatic and Extra-Hepatic Insulin Action in People With Type 2 Diabetes

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Abstract

OBJECTIVE—To determine mechanisms by which pioglitazone and metformin effect hepatic and extra-hepatic insulin action. RESEARCH DESIGN AND METHODS—Thirty-one subjects with type 2 diabetes were randomly assigned to pioglitazone (45 mg) or metformin (2,000 mg) for 4 months. RESULTS—Glucose was clamped before and after therapy at ∼5 mmol/l, insulin raised to ∼180 pmol/l, C-peptide suppressed with somatostatin, glucagon replaced at ∼75 pg/ml, and glycerol maintained at ∼200 mmol/l to ensure comparable and equal portal concentrations on all occasions. Insulin-induced stimulation of glucose disappearance did not differ before and after treatment with either pioglitazone (23 ± 3 vs. 24 ± 2 μmol · kg−1 · min−1) or metformin (22 ± 2 vs. 24 ± 3 μmol · kg−1 · min−1). In contrast, pioglitazone enhanced (P < 0.01) insulin-induced suppression of both glucose production (6.0 ± 1.0 vs. 0.2 ± 1.6 μmol · kg−1 · min−1) and gluconeogenesis (n = 11; 4.5 ± 0.9 vs. 0.8 ± 1.2 μmol · kg−1 · min−1). Metformin did not alter either suppression of glucose production (5.8 ± 1.0 vs. 5.0 ± 0.8 μmol · kg−1 · min−1) or gluconeogenesis (n = 9; 3.7 ± 0.8 vs. 2.6 ± 0.7 μmol · kg−1 · min−1). Insulin-induced suppression of free fatty acids was greater (P < 0.05) after treatment with pioglitazone (0.14 ± 0.03 vs. 0.06 ± 0.01 mmol/l) but unchanged with metformin (0.12 ± 0.03 vs. 0.15 ± 0.07 mmol/l). CONCLUSIONS—Thus, relative to metformin, pioglitazone improves hepatic insulin action in people with type 2 diabetes, partly by enhancing insulin-induced suppression of gluconeogenesis. On the other hand, both drugs have comparable effects on insulin-induced stimulation of glucose uptake.

Overview

Integrity signals

Registry

Crossref · 10.2337/db07-0827

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 1

  1. Buse JB, Polonsky KS, Burant CF: Chapter 29: Type 2 Diabetes Mellitus. In Larsen:Williams Textbook of Endocrinology, 10th ed. Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, Eds. Philadelphia, PA, Saunders,2003, p.1427–1482

Cited by

See all 65

Metadata

Authors
Basu, R., Shah, P., Basu, A., Norby, B., Dicke, B., Chandramouli, V., Cohen, O., Landau, B. R., & Rizza, R. A.
Affiliations
  • Mayo Clinic (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • Case Western Reserve University (US)
  • Sheba Medical Center (IL)
Venue
Diabetes
Published
2008-01-01
Volume
57
Issue
1
Pages
24-31
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2156803989
Cited by
63
References
49
Citations by year
2026: 2 · 2025: 1 · 2023: 6 · 2022: 2 · 2021: 5 · 2020: 3 · 2019: 2 · 2018: 3 · 2017: 2 · 2016: 4 · 2015: 2 · 2014: 3 · 2013: 3 · 2012: 2
FWCI
5.12
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Mayo Clinic
  • U.S. Public Health Service
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK-14507, DK 29953)
  • National Center for Research Resources (RR-00585, U 54RR 24150-1, M01RR000585)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
pioglitazone, metformin, type 2 diabetes, insulin action, hepatic insulin action, glucose production, gluconeogenesis, free fatty acids, insulin sensitivity, thiazolidinediones, glucose clamp, C-peptide, glucagon, glycerol infusion, insulin resistance, antidiabetic drugs
MeSH terms
Pioglitazone, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Diet, Diabetic, Double-Blind Method, Drug Administration Schedule, Fatty Acids, Nonesterified, Female, Glucagon, Gluconeogenesis, Glycerol, Humans, Hypoglycemic Agents, Infusions, Intravenous, Insulin, Kinetics, Liver, Male, Metformin, Middle Aged, Placebos, Glucose Clamp Technique, Body Mass Index, Thiazolidinediones, Glycogenolysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.